Veru (VERU) Non Operating Investment Income (2023 - 2024)

Veru (VERU) posted quarterly Non Operating Investment Income of -$192030.0 for Q1 2024, up 49.45% quarter-over-quarter from -$379898.0 in Q4 2023.

Veru (VERU) Non Operating Investment Income (2023 - 2024) Analysis & Trends

Veru (VERU) has reported Non Operating Investment Income for 2 consecutive years, with -$192030.0 the latest figure, recorded in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Investment Income (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Veru	60.85 Mn	35.06 Mn	-	-

Download Data